AEGON ASSET MANAGEMENT UK Plc Sells 25,858 Shares of Bristol Myers Squibb Company $BMY

Key Points

• AEGON ASSET MANAGEMENT UK Plc reduced its stake in Bristol Myers Squibb by 11.3%, selling 25,858 shares to hold a total of 202,546 shares worth approximately $9.37 million as of the latest quarter.
• Institutional investors own 76.41% of Bristol Myers Squibb shares, with several funds increasing their stakes in the company during recent quarters.
• Bristol Myers Squibb recently declared a quarterly dividend of $0.62 per share, representing an annual yield of 5.7%, while the company has a dividend payout ratio of 100%.

AEGON ASSET MANAGEMENT UK Plc cut its stake in Bristol Myers Squibb Company (NYSE:BMY - Free Report) by 11.3% during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 202,546 shares of the biopharmaceutical company's stock after selling 25,858 shares during the period. AEGON ASSET MANAGEMENT UK Plc's holdings in Bristol Myers Squibb were worth $9,374,000 at the end of the most recent quarter.

Other hedge funds have also recently made changes to their positions in the company. New England Asset Management Inc. grew its holdings in shares of Bristol Myers Squibb by 0.8% in the first quarter. New England Asset Management Inc. now owns 39,476 shares of the biopharmaceutical company's stock worth $2,408,000 after purchasing an additional 305 shares during the last quarter. Commonwealth Equity Services LLC lifted its stake in Bristol Myers Squibb by 1.1% in the first quarter. Commonwealth Equity Services LLC now owns 1,288,407 shares of the biopharmaceutical company's stock worth $78,580,000 after acquiring an additional 13,959 shares during the period. Sage Capital Advisors llc lifted its stake in Bristol Myers Squibb by 60.7% in the second quarter. Sage Capital Advisors llc now owns 85,234 shares of the biopharmaceutical company's stock worth $3,946,000 after acquiring an additional 32,181 shares during the period. Ransom Advisory Ltd purchased a new stake in Bristol Myers Squibb in the first quarter worth about $843,000. Finally, Castle Rock Wealth Management LLC lifted its stake in Bristol Myers Squibb by 458.2% in the second quarter. Castle Rock Wealth Management LLC now owns 44,559 shares of the biopharmaceutical company's stock worth $2,088,000 after acquiring an additional 36,576 shares during the period. 76.41% of the stock is currently owned by institutional investors.

Insiders Place Their Bets

In related news, EVP David V. Elkins sold 56,000 shares of the stock in a transaction that occurred on Tuesday, September 2nd. The shares were sold at an average price of $47.33, for a total value of $2,650,480.00. Following the transaction, the executive vice president owned 167,379 shares in the company, valued at approximately $7,922,048.07. This represents a 25.07% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Company insiders own 0.09% of the company's stock.

Bristol Myers Squibb Stock Performance

Shares of Bristol Myers Squibb stock opened at $43.63 on Thursday. The firm has a market capitalization of $88.81 billion, a P/E ratio of 17.59, a PEG ratio of 2.26 and a beta of 0.33. The company has a quick ratio of 1.11, a current ratio of 1.21 and a debt-to-equity ratio of 2.54. The company has a 50 day moving average price of $46.16 and a 200 day moving average price of $47.79. Bristol Myers Squibb Company has a 52 week low of $42.96 and a 52 week high of $63.33.

Bristol Myers Squibb (NYSE:BMY - Get Free Report) last issued its quarterly earnings results on Thursday, July 31st. The biopharmaceutical company reported $1.46 earnings per share for the quarter, topping the consensus estimate of $1.07 by $0.39. Bristol Myers Squibb had a net margin of 10.58% and a return on equity of 80.04%. The company had revenue of $12.27 billion for the quarter, compared to the consensus estimate of $11.32 billion. During the same quarter in the prior year, the company earned $2.07 EPS. Bristol Myers Squibb's quarterly revenue was up .6% on a year-over-year basis. Bristol Myers Squibb has set its FY 2025 guidance at 6.350-6.650 EPS. Sell-side analysts expect that Bristol Myers Squibb Company will post 6.74 EPS for the current year.

Bristol Myers Squibb Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Monday, November 3rd. Investors of record on Friday, October 3rd will be issued a $0.62 dividend. This represents a $2.48 annualized dividend and a yield of 5.7%. The ex-dividend date is Friday, October 3rd. Bristol Myers Squibb's dividend payout ratio is 100.00%.

Analyst Ratings Changes

A number of analysts recently weighed in on BMY shares. Weiss Ratings reaffirmed a "hold (c-)" rating on shares of Bristol Myers Squibb in a research note on Tuesday. Daiwa America lowered shares of Bristol Myers Squibb from a "strong-buy" rating to a "hold" rating in a research note on Tuesday, August 5th. Daiwa Capital Markets lowered shares of Bristol Myers Squibb from an "outperform" rating to a "neutral" rating and set a $42.00 price objective for the company. in a research note on Tuesday, August 5th. Morgan Stanley reaffirmed a "hold" rating on shares of Bristol Myers Squibb in a research note on Thursday, July 31st. Finally, Citigroup reissued a "neutral" rating on shares of Bristol Myers Squibb in a research report on Monday. One research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and fifteen have issued a Hold rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of "Hold" and an average target price of $57.14.

About Bristol Myers Squibb

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.